Top Biotech Companies in Singapore (112)
Grifols is a global healthcare company that develops, produces and markets plasma-derived medicines, other biopharmaceuticals, and solutions in transfusion medicine. Its work spans plasma, diagnostics, and life sciences, and it develops and markets medicines, solutions, and services in more than 110 countries. Grifols says its mission is to improve people's health and well-being, with patients, donors, and society at the...
Powermatic Associates, Inc. is a privately-held distributor of sensor technology, motion control, and machine control equipment and parts. Founded in 1972, the company provides solutions used across various sectors, including industrial automation, HVAC, pumping, and material handling, focusing on reliability and sustainability in its product offerings.
Esco Lifesciences is a world-leading manufacturer and service provider of life science tools. Esco contributes to meeting the challenges of the 21st century with a diverse range of business units—Scientific, Medical, Healthcare, and Aster. The company continuously innovates its products to help clinical and industrial laboratories conduct successful research and development, quality control, and analysis. Esco continues to provide reliable...
ESCO's Top Stability & Growth Strengths
Market Expansion: Public signals indicate the company opened a China headquarters in 2025, brought South Korea sales/service in‑house in 2024, and expanded EU manufacturing with a new Lithuania plant, alongside partnerships that broaden reach. Evidence also highlights sales in 100+ countries and operations spanning 24 countries, pointing to a broad and active commercial footprint.
Investor Backing & Capital Strength: A record-setting, oversubscribed US$200M Series A in 2021 led by Novo Holdings and Vivo Capital signals strong institutional confidence and funding for expansion, M&A, and R&D. Subsequent acquisitions, facility openings, and partnerships align with the stated use of proceeds and reinforce capital-enabled growth.
Strong Market Position & Advantage: Multiple independent market summaries consistently list the company among top global competitors in biosafety cabinets and clean‑air workstations, indicating leadership within that segment. A large installed base and global operations presence reinforce recognition across labs, hospitals, and biopharma.
Accelerating biological understanding and discovery is more than a mission for 10x Genomics. It’s a commitment. Fueled by equal parts scientific vision and determined passion, we are enabling fundamental research across the life sciences by delivering rapid innovation that allows our customers to resolve complex biology—across the fields of oncology, immunology, neuroscience, and more. As we deliver powerful new methods for...
10x Genomics's Top Stability & Growth Strengths
Strong Market Position & Advantage: 10x is widely regarded as the leader in single‑cell and a co‑leader in spatial biology, with Chromium, Visium and Xenium as reference platforms in many labs. Legal wins and injunctions in spatial further reinforce competitive positioning.
Product Line Growth: Ongoing chemistry and platform updates (GEM‑X, Visium HD, Xenium Protein/RNA multiomics) and launches like next‑gen Chromium Flex indicate continued expansion of content and capabilities. The planned acquisition of Scale Biosciences aims to broaden single‑cell workflows and support medium‑term growth.
Investor Backing & Capital Strength: The company maintains a sizable cash and securities balance alongside a large recurring consumables base. Management is prioritizing cash and costs while guiding quarter‑to‑quarter to navigate a softer funding environment.
We are a bunch of highly experienced doctors, technologists, insurance experts and managed care practitioners who believe that we can use technology to improve the quality of Asian healthcare while lowering costs. We also know what works in Asia, and we brought best-in-class technologies from around the world on to one platform to make that belief a reality. We get...
PSC Biotech is a life-sciences consulting and services company supporting organizations that develop and manufacture healthcare products. Founded in 1996, it helps pharmaceutical, biotechnology, and medical-device companies meet quality and regulatory requirements across the product lifecycle. Its work includes commissioning, qualification and validation, quality systems, regulatory affairs, engineering, metrology and calibration, technical staffing, and quality-management software for regulated life-sciences teams.
For over 240 years, Takeda’s propensity to evolve has driven the next generation of innovation, and as a future-focused organization, we’re continuing to drive forward with endurance in our steadfast pursuit to achieve the best outcomes for our patients in a rapidly changing world. We have been preparing for this period of value creation by investing in data, digital and...
Takeda's Top Stability & Growth Strengths
Strong Market Position & Advantage: Market position is reinforced by being the largest pharmaceutical company in Asia, a consistent top‑15–20 global player by revenue, and operations across roughly 80 countries.
Innovation-Driven Growth: Innovation momentum is evident through a first‑in‑class FDA‑approved narcolepsy treatment and positive late‑stage results for oveporexton and zasocitinib. Multiple priority reviews and planned launches further support the pipeline.
Profitability: Profitability is strengthening with a sharp increase in net profit and a significant rise in operating profit, accompanied by an upgraded full‑year outlook. Cost discipline and transformation initiatives are also helping protect earnings while investment rises.
Emancipation from network and security fears –NSPH architects a complete innovative network and security solution that will liberate your systems from network challenges and future vulnerability. NSPH established in Year 2002. It is now a leading regional VAD (Value-Added Distributor) in the area of IT Network and Security. Our headquarters is located in Singapore and we have offices in various...
Heilind Electronics is a global electronic components distributor specializing in interconnect, electromechanical, and sensor solutions. Founded in 1974, the company is recognized as a leading distributor of connectors and terminal blocks, particularly in North America. They provide access to an extensive inventory from over 170 world-class manufacturers, offering products such as relays, switches, and thermal management solutions with a customer-first...
Kemin Industries is a global ingredient manufacturer that strives to sustainably transform the quality of life every day for 80 percent of the world with its products and services. The company supplies over 500 specialty ingredients for human health, food safety and protection of the global food supply chain. Kemin ingredients offer solutions across various industries including animal health, nutraceuticals,...
4baseCare, an Illumina-backed Company* headquartered in Singapore, is engaged in developing cutting-edge Precision Oncology Solutions using Advanced Genomics and Next-Gen digital health technology. Taking into consideration that the clinical outcome could significantly vary across different populations, we have developed a unique set of indigenous comprehensive cancer gene panels that enables oncologists to choose the optimal precision therapies for their patients. Our...
Established in 2001, Avalere Health is a purposefully built commercialization partner for the biopharmaceutical, medical technology, and wellness industries. Our team of 1,500+ experts combine their knowledge and expertise across our core disciplines—Consulting; Medical; Policy; Value, Evidence, and Access; Marketing; and Digital Experience Technology—to create the connections that make better health happen. We partner with our clients to navigate the...
Avalere Health's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Revenue expanded in consecutive years, with double‑digit growth in 2023 followed by continued albeit slower growth in 2024. Trade coverage frames 2024 as a cooling market overall, suggesting the company’s trajectory reflects resilience amid a softer cycle.
Strong Market Position & Advantage: Industry rankings place the firm consistently in the MM+M Agency 100 top 20 in 2024–2025. External awards and frequent policy visibility reinforce stature in core North American healthcare‑agency and U.S. policy/access segments.
Future-Ready Strategy: Leadership additions, a unifying rebrand, and integration of advisory, medical, access, and marketing indicate a connected commercialization model. New offerings, AI/data‑driven tools, partnerships, and the “Every Patient Possible” mission signal preparation for evolving client needs.
We’re TD SYNNEX (NYSE: SNX), a leading distributor and solutions aggregator for the IT ecosystem. We’re 22,000 of the IT industry’s best and brightest, who share an unwavering passion for bringing compelling technology products, services and solutions to the world. We’re an innovative partner that helps our customers maximize the value of IT investments, demonstrate business outcomes and unlock growth opportunities. At...
TD SYNNEX's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent channel analysts and repeated vendor awards place the company at or near the top globally, with 2024 gross billings around $80B and leadership versus Ingram Micro and Arrow. Global reach across 100+ countries and extensive vendor relationships underscores durable ecosystem influence.
Strong Revenue Growth: Recent quarters show revenue up 9.7% year over year in Q4 FY2025 and full-year FY2025 up roughly 6.9%, with non‑GAAP gross billings up 14.7% and records set for billings and earnings. Near‑term guidance for Q1 FY2026 indicates continued year‑over‑year growth if executed.
Healthy Cash Flow: Q4 FY2025 generated about $1.4B in free cash flow alongside strong operating cash flow. The company raised its dividend and continued buybacks, reflecting increased cash returns as performance accelerated late in FY2025.
Entobel is converting low value organic substrate into high quality products thanks to insects. Our main current products are sustainable animal feed (proteins and oils) and organic fertilizer. Since 2013, Entobel is running a commercial scale production site in Vietnam and exporting products worldwide. Entobel complies with highest standards in the industry (ISO 22000), only use tracable feedstocks and is...
Catalent Inc. (NYSE: CTLT), an S&P 500® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health...
At Fusion Worldwide, we have spent more than 20 years sourcing electronics components for our customers. We use our supplier network to help resolve supply chain imbalances and keep your business on track. Whether solving for fluctuating pricing or lengthy lead times, Fusion is here to help you and your business pivot and react to changes quickly.
Cytek Biosciences develops cell-analysis solutions for biomedical researchers, pharmaceutical companies, contract research organizations, and academic institutions. Its platform centers on patented Full Spectrum Profiling technology and includes flow cytometry instruments and cell sorters, imaging systems, reagents, software, and services. By analyzing the full spectrum of fluorescent signals, these tools enable sensitive, high-content cellular analysis and help scientists obtain deeper biological...
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Illumina's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests Illumina maintains dominant leadership in short-read NGS with a broad installed base, end-to-end workflows, and wide adoption across research and clinical markets. This entrenched position supports recurring consumables pull-through and reinforces competitive advantage.
Profitability: Feedback suggests profitability and margins improved with a stronger year-end quarter, rising EPS, and robust free cash generation supporting restructuring and reinvestment. Operating performance strengthened year over year, indicating better cost discipline and a healthier earnings profile.
Innovation-Driven Growth: Feedback suggests product and technology innovation—including NovaSeq X adoption and advances in AI/informatics—is driving utilization and clinical momentum. Partnerships and acquisitions broaden multiomics capabilities and underpin a roadmap focused on further cost and throughput gains.
Mouser Electronics is a worldwide leading authorized distributor of semiconductors and electronic components from over 1,100 manufacturer brands. We specialize in the rapid introduction of new products and technologies for design engineers and buyers. Our extensive product offering includes semiconductors, interconnects, passives, and electromechanical components. In 2007, Mouser became a part of the Warren Buffett Berkshire Hathaway family of companies. Today,...
Mouser Electronics's Top Stability & Growth Strengths
Strong Market Position & Advantage: Industry accounts position Mouser as a leader among authorized, high‑service distributors, with frequent “Distributor of the Year” awards and consistent inclusion on top distributor rankings. Its authorized model, NPI emphasis, and large automated Texas distribution center bolster competitive differentiation.
Product Line Growth: The line card expanded with 63 new manufacturers in 2025 and over 40,000 new parts, adding to a catalog of more than 6.8 million products from 1,200+ brands. This continued NPI‑led breadth supports design engineers and small‑to‑mid volume buyers.
Investor Backing & Capital Strength: As part of TTI within Berkshire Hathaway, the company benefits from financial stability and group scale. Parent disclosures highlight a 2025 rebound at TTI and ongoing investments in large‑scale warehouse automation and footprint expansion.
Mirxes is a Singapore-headquartered biotechnology company whose mission is to save lives through early, actionable, and personalized diagnoses across the care continuum. We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide. Our flagship product is GASTROClear,...
